157 related articles for article (PubMed ID: 37499799)
1. Body surface area compared to body weight dosing of valganciclovir is associated with increased toxicity in pediatric solid organ transplantation recipients.
Demirhan S; Munoz FM; Valencia Deray KG; Bocchini CE; Danziger-Isakov L; Blum S; Sharma TS; Sherman G; Boguniewicz J; Bacon S; Ardura MI; Maron GM; Ferrolino J; Foca M; Herold BC
Am J Transplant; 2023 Dec; 23(12):1961-1971. PubMed ID: 37499799
[TBL] [Abstract][Full Text] [Related]
2. Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight-based dosed valganciclovir prophylaxis.
Liverman R; Serluco A; Nance G; George R; Rodriguez DS; Deshpande S; Mao C; Garro R; Yildirim I
Pediatr Transplant; 2023 Jun; 27(4):e14493. PubMed ID: 36945819
[TBL] [Abstract][Full Text] [Related]
3. A national survey of valganciclovir dosing strategies in pediatric organ transplant recipients.
Shaikh S; Jasiak-Panek N; Park JM
Clin Transplant; 2018 Sep; 32(9):e13369. PubMed ID: 30076649
[TBL] [Abstract][Full Text] [Related]
4. Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients: A Prospective Pharmacokinetic Study.
Peled O; Berkovitch M; Rom E; Bilavsky E; Bernfeld Y; Dorfman L; Pappo A; Ziv-Baran T; Brandriss N; Bar-Haim A; Amir J; Ashkenazi-Hoffnung L
Pediatr Infect Dis J; 2017 Aug; 36(8):745-750. PubMed ID: 28383392
[TBL] [Abstract][Full Text] [Related]
5. Antiviral toxicities in pediatric solid organ transplant recipients.
Hayes M; Boge CLK; Sharova A; Vader D; Mitrou M; Galetaki DM; Li Y; Downes KJ
Am J Transplant; 2022 Dec; 22(12):3012-3020. PubMed ID: 35971847
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of valganciclovir's neutropenia risk in pediatric solid organ transplant recipients utilizing two dosing regimens.
Patel A; Le K; Panek N
Pediatr Transplant; 2024 Mar; 28(2):e14714. PubMed ID: 38420722
[TBL] [Abstract][Full Text] [Related]
7. Incidence of valganciclovir-related leukopenia and neutropenia in solid organ transplant recipients at high risk of cytomegalovirus disease.
Belga S; Hernandez C; Kabbani D; Cervera C
Transpl Infect Dis; 2024 Apr; 26(2):e14227. PubMed ID: 38180285
[TBL] [Abstract][Full Text] [Related]
8. Reduced dosing versus full dosing valganciclovir for prophylaxis of cytomegalovirus in high-risk abdominal transplant recipients.
Kreiser ML; Dupuis R; Szempruch KR; Chargualaf LM
Clin Transplant; 2023 Oct; 37(10):e15041. PubMed ID: 37256906
[TBL] [Abstract][Full Text] [Related]
9. Impact of the patient's body weight on the efficacy and adverse events of valganciclovir for cytomegalovirus reactivation after hematopoietic stem cell transplantation.
Misaki Y; Kimura SI; Kawamura M; Kawamura S; Takeshita J; Yoshino N; Yoshimura K; Gomyo A; Matsumi S; Akahoshi Y; Tamaki M; Kusuda M; Kameda K; Wada H; Kawamura K; Sato M; Terasako-Saito K; Tanihara A; Nakasone H; Kako S; Kanda Y
Transpl Infect Dis; 2020 Jun; 22(3):e13270. PubMed ID: 32092224
[TBL] [Abstract][Full Text] [Related]
10. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy.
Kalil AC; Freifeld AG; Lyden ER; Stoner JA
PLoS One; 2009; 4(5):e5512. PubMed ID: 19436751
[TBL] [Abstract][Full Text] [Related]
11. Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Solid-organ Transplant Recipients on Continuous Veno-venous Hemodialysis.
Jarrell AS; Crow JR; Strout SE; Kruer RM; Toman LP; Dioverti-Prono MV; Lees L; Avery RK; Marzinke MA
Clin Infect Dis; 2021 Jul; 73(1):101-106. PubMed ID: 32379860
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology and long-term outcomes of cytomegalovirus DNAemia and disease in pediatric solid organ transplant recipients.
Valencia Deray KG; Hosek KE; Chilukuri D; Dunson JR; Spielberg DR; Swartz SJ; Spinner JA; Leung DH; Moulton EA; Munoz FM; Demmler-Harrison GJ; Bocchini CE
Am J Transplant; 2022 Jan; 22(1):187-198. PubMed ID: 34467658
[TBL] [Abstract][Full Text] [Related]
13. Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis.
Wong DD; van Zuylen WJ; Novos T; Stocker S; Reuter SE; Au J; Foster CSP; Day RO; Horvath AR; Endre Z; Rawlinson WD
Microbiol Spectr; 2022 Jun; 10(3):e0268421. PubMed ID: 35658598
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of a Weight-based Dosing Regimen of Valganciclovir for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients.
Pappo A; Peled O; Berkovitch M; Bilavsky E; Rom E; Amir J; Krause I; Yarden-Bilavsky H; Scheuerman O; Ashkenazi-Hoffnung L
Transplantation; 2019 Aug; 103(8):1730-1735. PubMed ID: 31343571
[TBL] [Abstract][Full Text] [Related]
15. Comparison of standard versus low-dose valganciclovir regimens for cytomegalovirus prophylaxis in high-risk liver transplant recipients.
Bixby AL; Fitzgerald L; Park JM; Kaul D; Tischer S
Transpl Infect Dis; 2021 Oct; 23(5):e13713. PubMed ID: 34428337
[TBL] [Abstract][Full Text] [Related]
16. Impact of standardized protocols for cytomegalovirus disease prevention in pediatric solid organ transplant recipients.
Ganapathi L; Blumenthal J; Alawdah L; Lewis L; Gilarde J; Jones S; Milliren C; Kim HB; Sharma TS
Pediatr Transplant; 2019 Nov; 23(7):e13568. PubMed ID: 31515909
[TBL] [Abstract][Full Text] [Related]
17. Antiviral dosing and efficacy for prophylaxis of cytomegalovirus disease in solid organ transplant recipients.
Cochrane AB
Am J Health Syst Pharm; 2006 Oct; 63(19 Suppl 5):S17-21. PubMed ID: 16990640
[TBL] [Abstract][Full Text] [Related]
18. Low-Dose Valganciclovir Prophylaxis Is Safe and Cost-Saving in CMV-Seropositive Kidney Transplant Recipients.
Shi Y; Lerner AH; Rogers R; Vieira K; Merhi B; Mecadon K; Osband AJ; Bayliss G; Gohh R; Morrissey P; Farmakiotis D
Prog Transplant; 2021 Dec; 31(4):368-376. PubMed ID: 34839729
[No Abstract] [Full Text] [Related]
19. Valganciclovir prophylaxis for cytomegalovirus infection in pediatric kidney transplant recipients: a single-center experience.
Iida T; Miura K; Ban H; Ando T; Shirai Y; Ishiwa S; Shiratori A; Kaneko N; Yabuuchi T; Ishizuka K; Takaiwa M; Suyama K; Hisano M; Hattori M
Clin Exp Nephrol; 2021 May; 25(5):531-536. PubMed ID: 33506359
[TBL] [Abstract][Full Text] [Related]
20. GCV/VCVG prophylaxis against CMV DNAemia in pediatric renal transplant patients: A systematic review and meta-analysis.
Chatani B; Glaberson W; Nemeth Z; Tamariz L; Gonzalez IA
Pediatr Transplant; 2019 Sep; 23(6):e13514. PubMed ID: 31210393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
